A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract-Reference-Cited by-同舟云学术

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

Published:2020-12-31 Issue:3 Volume:10 Page:1074-1083
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Sarfaty Michal¹²^ORCID,Whiting Karissa³^ORCID,Teo Min Yuen¹⁴^ORCID,Lee Chung‐Han¹⁴^ORCID,Peters Vanessa¹,Durocher Jennifer¹,Regazzi Ashley M.¹^ORCID,McCoy Asia S.¹,Hettich Grace¹,Jungbluth Achim A.⁵,Al‐Ahmadie Hikmat⁵^ORCID,Ostrovnaya Irina³,Chaim Joshua⁶,Bajorin Dean F.¹⁴,Rosenberg Jonathan E.¹⁴^ORCID,Iyer Gopa¹⁴^ORCID,Funt Samuel A.¹⁴^ORCID

Affiliation:

1. Genitourinary Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

2. Davidoff Cancer Center Petah‐Tikva, Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel

3. Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York NY USA

4. Weill Cornell Medical College New York NY USA

5. Department of Pathology Memorial Sloan Kettering Cancer Center New York NY USA

6. Department of Radiology Memorial Sloan Kettering Cancer Center New York NY USA

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3699

Reference55 articles.

1. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

2. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

3. Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications

4. Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications;Modern Pathology;2024-10

2. Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer;American Society of Clinical Oncology Educational Book;2024-06

3. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application;Frontiers in Immunology;2024-05-02

4. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way;European Journal of Pharmacology;2024-04

5. Updates on Urinary Bladder Tumors With Neuroendocrine Features;Advances in Anatomic Pathology;2024-03-25